Publications by authors named "Chibuike J Alanaeme"
Background: The prevalence of many chronic conditions has increased among US adults. Many adults with hypertension have other chronic conditions.
Methods: We estimated changes in the age-adjusted prevalence of multiple (≥3) chronic conditions, not including hypertension, using data from the National Health and Nutrition Examination Survey, from 1999-2000 to 2017-2020, among US adults with (n = 24,851) and without (n = 24,337 hypertension.
Healthcare utilization and cost barriers among U.S. childhood cancer survivors.
Pediatr Blood Cancer
August 2023
Background: To evaluate healthcare utilization and cost barrier patterns among childhood cancer survivors (CCS) compared with noncancer controls.
Procedure: Using the 2014-2019 Behavioral Risk Factor Surveillance System, we identified CCS < 50 years and matched controls. We used chi-squared tests to compare characteristics between the two groups.
Study Objective: The 2018 American Heart Association/American College of Cardiology (AHA/ACC) cholesterol guideline recommends a maximally-tolerated statin with add-on lipid-lowering therapy, ezetimibe and/or proprotein convertase subtilisin/kexin type 9 (PCSK9) for adults with very-high atherosclerotic cardiovascular disease (ASCVD) risk to achieve a low-density lipoprotein cholesterol (LDL-C) <70 mg/dL. We estimated the percentage of US adults with ASCVD recommended, by the 2018 AHA/ACC cholesterol guideline, and receiving add-on lipid-lowering therapy.
Design Setting And Participants: Cross-sectional study including 805 participants from the US National Health and Nutrition Examination Survey (NHANES) 2013-2020 data.
Background: In March and April 2020, medical societies published statements recommending continued use of renin-angiotensin system (RAS) inhibitors despite theoretical concerns that these medications could increase COVID-19 severity. Determining if patients discontinued RAS inhibitors during the COVID-19 pandemic could inform responses to future public health emergencies.
Methods: We analyzed claims data from US adults with health insurance in the Marketscan database.
Article Synopsis
- Clinical trials show that switching from the infliximab bio-originator to its biosimilar is safe and maintains efficacy, but real-world data on their use and adherence is limited.
- A study using IBM Marketscan data from 2015-2018 analyzed different patient cohorts based on their prior infliximab usage and calculated adherence rates over time.
- Findings indicated that adherence was higher among prevalent bio-originator users compared to naïve users, with certain factors like depression negatively impacting adherence, while age and specific diagnoses positively influenced it.